Search
Veligrotug
go.drugbank.com/drugs/DB18976Approved[L63798] Thyroid eye disease has historically been managed differently depending on whether it is caught in the active inflammatory phase or has become chronic - Viridian describes veligrotug-vvze as the … [L63798] Although its precise mechanism in thyroid eye disease has not been fully characterized, IGF-1R blockade reduces the proptosis and diplopia that define the condition.
Sinecatechins
go.drugbank.com/drugs/DB01266ApprovedInvestigationalNutraceuticalCatechins constitute 85 to 95% (by weight) of the total drug substance which includes more than 55% of Epigallocatechin gallate (EGCg), other catechin derivatives such as Epicatechin (EC), Epigallocatechin
Flutemetamol (18F)
go.drugbank.com/drugs/DB09151ApprovedInvestigationalIt is used to evaluate Alzheimer's disease (AD) or other causes of cognitive decline as an Aβ-specific positron emission tomography (PET) ligand.[L35029]
Alfuzosin
go.drugbank.com/drugs/DB00346ApprovedThe prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. … [L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.[L9251]
Recombinant stabilized RSV B prefusion F antigen
go.drugbank.com/drugs/DB18714ApprovedInvestigational[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of
Vestronidase alfa
go.drugbank.com/drugs/DB12366ApprovedInvestigationalVestronidase alfa was FDA-approved on November 17th, 2017 under the trade name Mepsevii as an intravenous infusion for the treatment of pediatric and adult patients. … The enzyme is a homotetramer consisted of 4 monomers with 629 amino acids, and holds the same amino acid sequence as human beta-glucuronidase (GUS) [FDA Label].
Aldesleukin
go.drugbank.com/drugs/DB00041ApprovedInvestigationalfor this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. … This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon
Formebolone
go.drugbank.com/drugs/DB01569IllicitInvestigationalIt has been used experimentally in the treatment of growth retardation, and has been noted to increase bone mass. … [A14416] It is also classified by the US Drug Enforcement Administration as Schedule III drug in the Controlled Substances Act.
Lodoxamide
go.drugbank.com/drugs/DB06794ApprovedMast-cell stabilizers, first one approved being cromolyn sodium, are used in treatment of ocular hypersensitivity reactions such as vernal conjunctivitis. … These conditions often require treatment with anti-inflammatory medications such as ophthalmic NSAIDs or topical steroids which may cause systemic or toxic effects long-term.
Picrotoxin
go.drugbank.com/drugs/DB00466ExperimentalAlthough it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. [PubChem]